{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PT001+MDI",
    "query": {
      "intervention": "PT001 MDI"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PT001+MDI&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T20:05:30.017Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01566773",
      "title": "PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT001 MDI",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium Bromide",
          "type": "DRUG"
        },
        {
          "name": "PT001 Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 140,
      "start_date": "2012-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-12",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 10,
      "location_summary": "Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Panama City",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01566773"
    },
    {
      "nct_id": "NCT01587079",
      "title": "Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium inhalation powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-04",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-30",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 19,
      "location_summary": "Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01587079"
    },
    {
      "nct_id": "NCT02196714",
      "title": "PK Study of PT003 and PT001 in Japanese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196714"
    },
    {
      "nct_id": "NCT01350128",
      "title": "PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT001 MDI",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium Bromide HFA Inhalation Aerosol",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 103,
      "start_date": "2011-05-01",
      "completion_date": "2011-10-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-20",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 8,
      "location_summary": "Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more",
      "locations": [
        {
          "city": "Panama City",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01350128"
    },
    {
      "nct_id": "NCT01854645",
      "title": "Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "GFF MDI",
          "type": "DRUG"
        },
        {
          "name": "GP MDI",
          "type": "DRUG"
        },
        {
          "name": "FF MDI",
          "type": "DRUG"
        },
        {
          "name": "Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 2103,
      "start_date": "2013-05",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 121,
      "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854645"
    },
    {
      "nct_id": "NCT02433834",
      "title": "Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium MDI",
          "type": "DRUG"
        },
        {
          "name": "Serevent Diskus 50 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 248,
      "start_date": "2015-05-27",
      "completion_date": "2016-03-26",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02433834"
    },
    {
      "nct_id": "NCT03358147",
      "title": "Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "GP MDI 28.8 μg",
          "type": "DRUG"
        },
        {
          "name": "GP MDI 14.4 μg",
          "type": "DRUG"
        },
        {
          "name": "GP MDI 7.2 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        },
        {
          "name": "Spiriva Respimat 2.5 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 1077,
      "start_date": "2017-12-13",
      "completion_date": "2019-09-12",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 232,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03358147"
    },
    {
      "nct_id": "NCT02343458",
      "title": "Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT003)",
          "type": "DRUG"
        },
        {
          "name": "FF MDI (PT005)",
          "type": "DRUG"
        },
        {
          "name": "GP MDI (PT001)",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 1756,
      "start_date": "2015-03-30",
      "completion_date": "2017-08-31",
      "has_results": true,
      "last_update_posted_date": "2019-02-20",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 44,
      "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343458"
    },
    {
      "nct_id": "NCT01970878",
      "title": "Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "GFF MDI (PT 003)",
          "type": "DRUG"
        },
        {
          "name": "GP MDI (PT001)",
          "type": "DRUG"
        },
        {
          "name": "FF MDI (PT005)",
          "type": "DRUG"
        },
        {
          "name": "Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 892,
      "start_date": "2013-11",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 110,
      "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01970878"
    },
    {
      "nct_id": "NCT01349816",
      "title": "PT003 MDI Dose Confirmation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 185,
      "start_date": "2011-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-09-02T20:05:30.017Z",
      "location_count": 13,
      "location_summary": "Rancho Mirage, California • Colorado Springs, Colorado • Waterbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349816"
    }
  ]
}